Pular para o conteúdo principal
Ranking Invest

MYOV - Myovant Sciences Ltd.

Segmento: HealthcareMyovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Análise Ranking Invest

Valuation estimado
-$ 1.43 Bi
Último Balanço Atualizado: 3T2022

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

-$ 558.14 Mi

Dívida Líquida

$ 116.29 Mi

L4T

-$ 183.77 Mi

MM4T

-55.56%

Indicadores Básicos

ROE

32.93%

Índices de Previsibilidade

Receita Líquida

F0.61

Lucro

B0.22

Margem

D1.03

Índices de Tendência

Receita Líquida

A10.64

Lucro

B6.05

Margem

E-3.48

Índices de Endividamento

DIV/PAT

-0.21

DIV/L4T

-0.63

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.